• The Korean Journal of Pain
• /
• v.22 no.1
• /
• pp.16-20
• /
• 2009

Background: Zaprinast is an inhibitor of phosphodiesterase 5, 6 and 9. Phosphodiesterase inhibitors could produce anti-nociceptive effects by promoting the accumulation of cGMP. We hypothesized that intrathecal zaprinast could attenuate the allodynia induced by chronic constriction injury of the sciatic nerve in rat. Methods: Sprague-Dawley rats were prepared with four loose ligations of the left sciatic nerve just proximal to the trifurcation into the sural, peroneal and tibial nerve branches. Tactile allodynia was measured by applying von Frey filaments to the lesioned hindpaw. The thresholds for the withdrawal responses were assessed. Zaprinast ($3-100{\mu}g$) was administered intrathecally by the direct lumbar puncture method to obtain the dose-response curve and the 50% effective dose ($ED_{50}$). Measurements were taken before and 15, 30, 45, 60, 90, 120, and 180 min after the intrathecal doses of zaprinast. The side effects were also observed. Results: Intrathecal zaprinast resulted in a dose-dependent antiallodynic effect. The maximal effects occurred within 15-30 min and then they gradually decreased down to the baseline level over time in all the groups. There was a dose dependent increase in the magnitude and duration of the effect. The $ED_{50}$ value was $17.4{\mu}g$ (95% confidence intervals; $14.7-20.5{\mu}g$). No severe motor weakness or sedation was observed in any of the rats. Conclusions: Intrathecally administered zaprinast produced a dose-dependent antiallodynic effect in the chronic constriction injury neuropathic pain model. These findings suggest that spinal phosphodiesterase 5, 6 and 9 may play an important role in the modulation of neuropathic pain.

• Journal of Korean Neurosurgical Society
• /
• v.65 no.5
• /
• pp.665-679
• /
• 2022

Objective : Patients with mild ischemic stroke experience various sequela and residual symptoms, such as anxious behavior and deficits in movement. Few approaches have been proved to be effective and safe therapeutic approaches for patients with mild ischemic stroke by acute stroke. Sildenafil (SIL), a phosphodiesterase-5 inhibitor (PDE5i), is a known remedy for neurodegenerative disorders and vascular dementia through its angiogenesis and neurogenesis effects. In this study, we investigated the efficacy of PDE5i in the emotional and behavioral abnormalities in rats with mild ischemic stroke. Methods : We divided the rats into four groups as follows (n=20, respectively) : group 1, naïve; group 2, middle cerebral artery occlusion (MCAo30); group 3, MCAo30+SIL-pre; and group 4, MCAo30+SIL-post. In the case of drug administration groups, single dose of PDE5i (sildenafil citrate, 20 mg/kg) was given at 30-minute before and after reperfusion of MCAo in rats. After surgery, we investigated and confirmed the therapeutic effect of sildenafil on histology, immunofluorescence, behavioral assays and neural oscillations. Results : Sildenafil alleviated a neuronal loss and reduced the infarction volume. And results of behavior task and immunofluorescence shown possibility that anti-inflammation process and improve motor deficits sildenafil treatment after mild ischemic stroke. Furthermore, sildenafil treatment attenuated the alteration of theta-frequency rhythm in the CA1 region of the hippocampus, a known neural oscillatory marker for anxiety disorder in rodents, induced by mild ischemic stroke. Conclusion : PDE5i as effective therapeutic agents for anxiety and movement disorders and provide robust preclinical evidence to support the development and use of PDE5i for the treatment of mild ischemic stroke residual disorders.

• Proceedings of the Korea Environmental Mutagen Society Conference
• /
• 2003.05a
• /
• pp.43-44
• /
• 2003

• Proceedings of the Korean Society for Applied Microbiology Conference
• /
• 1978.10a
• /
• pp.205.1-205
• /
• 1978

일반적으로 쌀막걸리 중에는 풍미에 관여한다고 생각되는 핵산관련물질이 핵산분해효소인 PDase (phosphodiesterase) 및 PMase (phospomonoesterase) 등의 작용을 받아 대부분이 분해되는 것으로 알려져 있다. 따라서 저자등은 쌀막걸리 제조공정을 통하여 핵산관련물질의 분포와 그와 관련된 핵산 분해효소에 대한 실험을 하였다. 본보에서는 제국중 핵산관련물질과 핵산관련물질을 분해하는 효소의 경시적 변화를 조사하였으며 이들 분해효소의 효소학적 성질을 검토하여 몇가지 결과를 얻었으므로 보고하는 바이다.

• Archives of Pharmacal Research
• /
• v.12 no.4
• /
• pp.276-281
• /
• 1989

Selective inhibition of seven new PDE inhibitors on cyclic nucleotide PDE isozymes was investigated. Three PDE isozymes (PDE I, II and III) of guinea pig left ventricular muscles were used. All tested agents inhibited cyclic AMP hydrolysis by PDE III IN A concentration-dependent manner. Some agents represented more potent and selective inhibitory effect on PDE III than that of imazodan.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 2002.07a
• /
• pp.204-204
• /
• 2002

• 대한임상약리학회:학술대회논문집
• /
• 2007.11a
• /
• pp.86-86
• /
• 2007

See Full Text

• Proceedings of the Korea Environmental Mutagen Society Conference
• /
• 2002.05a
• /
• pp.114-114
• /
• 2002

• Proceedings of the PSK Conference
• /
• 2001.10a
• /
• pp.138.1-138.1
• /
• 2001

• Proceedings of the PSK Conference
• /
• 2003.04a
• /
• pp.207.2-207.2
• /
• 2003

cAMP acts as a second messenger in the functional responses of various cells to hormones, cytokines and other agents. In turn, this nucleotide also modulates the signal transduction processes regulated by a range of cytokines and growth factors. The intracellular level of cAMP is regulated by a G protein coupled adenylyl cyclase and degradation is mediated by the phosphodiesterases (PDEs), a superfamily of enzymes that catalyze the hydrolysis of cAMP. (omitted)